BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37446260)

  • 41. Neutrophil Extracellular Traps Promote T Cell Exhaustion in the Tumor Microenvironment.
    Kaltenmeier C; Yazdani HO; Morder K; Geller DA; Simmons RL; Tohme S
    Front Immunol; 2021; 12():785222. PubMed ID: 34899751
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
    Pinto N; Park JR; Murphy E; Yearley J; McClanahan T; Annamalai L; Hawkins DS; Rudzinski ER
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28488345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Overexpression of Programmed Death-Ligand 2 in Uterine Adenosarcoma: Correlation with High-Grade Morphology, Mutant Type TP53 Expression and Clinical Outcomes.
    Ok Atılgan A; Yılmaz Akçay E; Özen Ö; Haberal Reyhan AN; Ayhan A
    Int J Surg Pathol; 2023 Jun; 31(4):352-364. PubMed ID: 35466759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of tumor microenvironment in cancer progression and therapeutic strategy.
    Wang Q; Shao X; Zhang Y; Zhu M; Wang FXC; Mu J; Li J; Yao H; Chen K
    Cancer Med; 2023 May; 12(10):11149-11165. PubMed ID: 36807772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer.
    Mo Z; Liu J; Zhang Q; Chen Z; Mei J; Liu L; Yang S; Li H; Zhou L; You Z
    Oncol Lett; 2016 Aug; 12(2):944-950. PubMed ID: 27446374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment.
    Lv J; Jiang Z; Yuan J; Zhuang M; Guan X; Liu H; Yin Y; Ma Y; Liu Z; Wang H; Wang X
    Front Immunol; 2023; 14():1093716. PubMed ID: 37006239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic and Clinical Value of Interleukin 6 and CD45
    Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
    J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
    Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
    Front Immunol; 2019; 10():1644. PubMed ID: 31379843
    [No Abstract]   [Full Text] [Related]  

  • 51. Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma.
    London NR; Rooper LM; Bishop JA; Xu H; Bernhardt LJ; Ishii M; Hann CL; Taube JM; Izumchenko E; Gaykalova DA; Gallia GL
    World Neurosurg; 2020 Mar; 135():e187-e193. PubMed ID: 31785431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Retinoblastoma Is Characterized by a Cold, CD8+ Cell Poor, PD-L1- Microenvironment, Which Turns Into Hot, CD8+ Cell Rich, PD-L1+ After Chemotherapy.
    Miracco C; Toti P; Gelmi MC; Aversa S; Baldino G; Galluzzi P; De Francesco S; Petrelli F; Sorrentino E; Belmonte G; Galimberti D; Bracco S; Hadjistilianou T
    Invest Ophthalmol Vis Sci; 2021 Feb; 62(2):6. PubMed ID: 33538768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma.
    Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Zheng W; Castrillon DH; Lucas E
    Mod Pathol; 2022 Dec; 35(12):1955-1965. PubMed ID: 35804040
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
    Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
    Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
    Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.
    Yang L; Huang F; Mei J; Wang X; Zhang Q; Wang H; Xi M; You Z
    Int J Gynecol Cancer; 2017 Feb; 27(2):196-205. PubMed ID: 27870715
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
    Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
    Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.